Piperidine derivatives as HDAC1/2 inhibitors
Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
1. A compound selected from:
or pharmaceutically acceptable salts thereof.
2. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
3. A method for treating a disease mediated by HDAC1 and/or HDAC2 in a subject in need thereof, comprising administering a compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the disease mediated by HDAC1 and/or HDAC2 in is selected from a group consisting of sickle-cell disease, beta-thalassemia, lung cancer, colon cancer, breast cancer, neuroblastoma, leukemia and lymphoma.
4. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.